Added to YB: 2026-07-20
Pitch date: 2026-07-15
AVCT.L [bullish]
Avacta Group Plc
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally.
Market Cap
GBP 320.9M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-11.24
P/E
-7.55
EV/Sales
2.8K
Sector
Biotechnology
Category
special_situation
Show full summary:
Equity Research Report: Avacta Group plc (LON: $AVCT)
AVCT.L: UK clinical-stage oncology biotech, pure-play post diagnostics divestment. pre|CISION FAPα-cleaved peptide-drug conjugate platform; lead AVA6000 got FDA single pivotal trial nod (salivary gland cancer, 90% DCR). Runway into Q1'27. Trades £323M cap vs £468-475M rNPV. Catalysts: AVA6103 Ph1 H2'26, partnering.
Read full article (8 min)